← Back to Clinical Trials
Recruiting NCT07248202

NCT07248202 Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia in Patients With Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07248202
Status Recruiting
Phase
Sponsor Cairo University
Condition Coronary Artery Disease (CAD)
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-12-01
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Fentanyl (IV)lidocaine

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-12-01 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study compares ketamine/fentanyl versus ketamine/lidocaine in term of their impact on cerebral perfusion during CABG. No prior data address these effects, and the goal is to identify the induction regimen that better preserves cerebral oxygenation.

Eligibility Criteria

Inclusion Criteria: * patients with coronary artery disease * with moderate to severe left ventricular dysfunction (ejection fraction \< 40%), * scheduled for elective CABG surgery Exclusion Criteria: * associated chronic stroke, TIA , carotid occlusive disease( due to abnormal vasomotor activity), patients with known neurological impairment (cerebral infarction , dementia ), significant carotid artery stenosis , * valvular heart disease, * persistent arrhythmias, * congestive cardiac failure, * on mechanical ventilation, * intra-aortic balloon pump, * emergency surgery, * and those with known allergy to any of the study's drugs, * severe systemic non-cardiac disease and * patients with baseline NIRS reading \< 60% * Patients with dementia or visual or auditory impairment

Contact & Investigator

Central Contact

Maha Mostafa

✉ maha.mostafa@cu.edu.eg

📞 +201000365115

Frequently Asked Questions

Who can join the NCT07248202 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, studying Coronary Artery Disease (CAD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07248202 currently recruiting?

Yes, NCT07248202 is actively recruiting participants. Contact the research team at maha.mostafa@cu.edu.eg for enrollment information.

Where is the NCT07248202 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07248202 clinical trial?

NCT07248202 is sponsored by Cairo University. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology